Small caps round-up: ReNeuron, Havelock, Goodwin
Clinical-stage stem cell group ReNeuron has achieved further significant milestones with its ReN001 and ReN009 programmes in stroke and critical limb ischaemia, with the filing of two further clinical trial applications to progress the clinical development of these novel therapies. Michael Hunt, Chief Executive Officer of ReNeuron, told shareholders at the company's annual general meeting that the firm remains funded for the next 12 months, but will pursue a range of funding options including non-dilutive grants.
Clinical-stage stem cell group ReNeuron has achieved further significant milestones with its ReN001 and ReN009 programmes in stroke and critical limb ischaemia, with the filing of two further clinical trial applications to progress the clinical development of these novel therapies. Michael Hunt, Chief Executive Officer of ReNeuron, told shareholders at the company's annual general meeting that the firm remains funded for the next 12 months, but will pursue a range of funding options including non-dilutive grants.
Shopfitter Havelock Europe saw group revenue from continuing operations rise by 17% to £38.5m in the first half of 2012 from £32.9m the year before. The underlying pre-tax loss narrowed to £1.2m from a loss of £2.8m the previous year. The good news is that the company made a profit after tax of £7.3m, versus a loss of £1.1m in the first half of 2011, after trousering an exceptional gain of £8.0m from the sale of its print division. Group net debt eased to £2.3m from £13.7m. "Looking ahead, the markets will continue to remain challenging. However, we are in a much stronger position to deliver continued progress in the second half aided by an increased order book both in the UK and overseas," revealed Eric Prescott, Havelock's CHief Executive Officer.
Engineering and steel castings firm Goodwin said its first quarter performance was in line with expectations. Revenue in the three months to July 31st rose to £30.39m from £26.00m in the corresponding period of 2011, while profit before tax surged to £3.76m from £2.43m a year earlier.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
JH
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?
Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
By Kalpana Fitzpatrick Published
-
What does Rachel Reeves’s plan for growth mean for UK investors?
Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
By Katie Williams Published